Article
Next-generation sequencing methodologies to identify patients for targeted therapy: focus on HR+/HER2- metastatic breast cancer.
Pathologica - 1 Dec 2025
Malapelle Umberto, Buglioni Simonetta, Castellano Isabella, Criscitiello Carmen, Curigliano Giuseppe, d'Amati Giulia, De Angelis Carmine, de Biase Dario, Pepe Francesco, Perrone Giuseppe, Scatena Cristian, Scatolini Maria, Trapani Dario, Venetis Konstantinos, Fusco Nicola
Abstract excerpt
Alterations in the phosphoinositide 3-kinase (PI3K)/AKT/PTEN signaling pathway are a well-recognized mechanism of resistance in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- mBC). These alterations are present in approximately half of patients with HR+/HER2- mBC. The major alterations in the pathway are somatic mutations in the PIK3CA (40-45%) and AKT1 (5%) genes, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.